2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
May 2026 in “International Journal of Molecular Sciences” Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.
February 2026 in “Eduvest - Journal Of Universal Studies” Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
56 citations
,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
32 citations
,
April 2019 in “JAAD case reports” JAK inhibitors helped treat hair loss in two people with Down syndrome.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
19 citations
,
August 2019 in “Dermatologic therapy” Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
11 citations
,
June 2019 in “Journal of dermatology” New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
11 citations
,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
8 citations
,
November 2024 in “EMBO Molecular Medicine” Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
4 citations
,
April 2020 in “JAAD case reports” JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.